{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:53:39Z","timestamp":1787061219203,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet Med"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>While randomized controlled trials data on the long\u2010term effect of glucose\u2010lowering drugs (GLDs) on liver\u2010related outcomes are lacking, population\u2010based studies have evaluated the associations of GLDs with liver\u2010related outcomes in individuals with type 2 diabetes (T2D). we aimed to conduct a systematic review of population\u2010based studies evaluating the effects of GLDs on liver\u2010related outcomes in people with T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Web of Science, and Embase databases were systematically searched for population\u2010based studies testing the associations of GLDs with liver\u2010related outcomes in individuals with T2D and no liver disease other than non\u2010alcoholic fatty liver disease (NAFLD) from inception to 23 February 2024. GLDs included SGLT2is, TZDs, insulin, GLP\u20101 RAs and dipeptidyl peptidase\u20104 inhibitors (DPP4Is).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten cohort studies, comprising 1,274,641 participants, met the inclusion criteria. The median follow\u2010up period ranged from 8.9 to 76\u2009months. Of all the GLDs under investigation, SGLT2is were associated with the strongest reduction in NAFLD incidence, cirrhosis, and composite liver\u2010related events compared to other medications. TZDs were associated with a reduced risk of developing NAFLD and cirrhosis but were not significantly associated with a lower incidence of hepatocellular carcinoma. GLP\u20101 RAs demonstrated a significant association with reduced liver\u2010related mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Observational data from population\u2010based studies suggest that GLDs such as SGLT2is are associated with beneficial long\u2010term liver\u2010related outcomes in T2D patients with NAFLD. Additional studies, including randomized controlled trials with long\u2010term follow\u2010up, are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration Number<\/jats:title>\n                    <jats:p>PROSPERO CRD442024536872.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dme.15437","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T11:44:34Z","timestamp":1727523874000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Glucose\u2010lowering drugs and liver\u2010related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population\u2010based studies"],"prefix":"10.1111","volume":"41","author":[{"given":"Shaghayegh","family":"Khanmohammadi","sequence":"first","affiliation":[{"name":"Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Tehran University of Medical Sciences Tehran Iran"},{"name":"Non\u2010Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Habibzadeh","sequence":"additional","affiliation":[{"name":"School of Medicine Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B. M.","family":"Kamrul\u2010Hasan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Mymensingh Medical College Mymensingh Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Art","family":"Schuermans","sequence":"additional","affiliation":[{"name":"Faculty of Medicine KU Leuven Leuven Belgium"},{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative Broad Institute of Harvard and MIT Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-6137","authenticated-orcid":false,"given":"Mohammad Shafi","family":"Kuchay","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Medanta the Medicity Hospital Gurugram India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0086"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106507"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.773342"},{"key":"e_1_2_10_7_1","unstructured":"FDA.FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease.2024Available from:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010treatment\u2010patients\u2010liver\u2010scarring\u2010due\u2010fatty\u2010liver\u2010disease"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107706"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2022.100437"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399820666230525150437"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13026"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2016.11.009"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.001"},{"key":"e_1_2_10_14_1","volume-title":"The Newcastle\u2010Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta\u2010Analyses","author":"Wells GA","year":"2011"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294423"},{"key":"e_1_2_10_16_1","first-page":"375","article-title":"Outcomes of various classes of Oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA","volume":"184","author":"Jang H","year":"2024","journal-title":"Intern Med"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327504"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1953"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32012"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14385"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03228-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.04.029"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330962"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","article-title":"Association of glucagon\u2010like peptide\u20101 receptor agonists with serious liver events among patients with type 2 diabetes: a scandinavian cohort study","volume":"79","author":"Engstr\u00f6m A","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006888"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57935-6"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.249"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33743"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861"},{"issue":"7","key":"e_1_2_10_33_1","first-page":"45","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli S","year":"2018","journal-title":"Fed Pract"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13335"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-016-0302-y"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52603-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001956"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13230"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1182037"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.15437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:03:12Z","timestamp":1732809792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.15437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/dme.15437"],"URL":"https:\/\/doi.org\/10.1111\/dme.15437","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15437"}}